Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options

Go online to PeerView.com/JPJ860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. The modern management of multiple myeloma (MM) continues to
be transformed by the emergence and further integration of
different antibody-based approaches into patient management. How
can professionals exploit these advances while using the principles
of shared decision-making when caring for patients? In this
activity, two hematologist-oncologists and a patient advocate
explore these themes through a case-based discussion of novel
antibody platforms in a range of MM treatment settings. Learners
can expect insights on the safety and efficacy evidence supporting
the use of antibody-based therapies in newly diagnosed and relapsed
MM, along with practical guidance for safe delivery of care, and
strategies for engaging with patients when developing treatment
plans that include antibody components. Upon completion of this
activity, participants should be better able to: Summarize current
evidence and guideline recommendations surrounding the use of novel
antibody platforms in multiple myeloma (MM); Integrate established
and emerging antibody options, including monoclonal and bispecific
antibodies, into treatment plans for patients with MM based on
guideline recommendations and the latest clinical data; Address
practical aspects of antibody therapy in MM, including unique
safety considerations and effective sequential treatment; and
Counsel patients with MM on dosing, safety, drug delivery, and
therapeutic expectations with novel antibodies when engaging in
shared decision-making discussions.